NCT07388563 2026-03-18
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
Clinical Trials
17 trialsNCT07366801 2026-01-26
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Recruiting
NCT06731504 2026-01-16
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
Duke University
Phase EARLY_PHASE1 Recruiting
NCT01743131 2025-12-11
Abatacept as GVHD Prophylaxis Phase 2
Boston Children's Hospital
Phase 2 Completed
NCT03680092 2025-10-02
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
University of California, San Diego
Phase 2 Completed
NCT05335928 2025-09-10
ATRIUM
Massachusetts General Hospital
Phase 3 Recruiting
NCT06680661 2025-06-04
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT03457142 2025-03-04
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Roswell Park Cancer Institute
Phase 2 Terminated
NCT06475820 2024-08-23
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Active not recruiting
NCT05515029 2023-09-28
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Active not recruiting
NCT04255134 2023-05-18
BIORA-PAIN
St George's, University of London
Phase 4 Completed
NCT03059888 2019-11-22
Trial of Orencia in Patients With Myasthenia Gravis
Johns Hopkins University
Phase EARLY_PHASE1 Terminated
NCT01012492 2019-11-21
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
Boston Children's Hospital
Phase 2 Completed
NCT01351480 2017-03-13
Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients
Arthritis & Rheumatic Disease Specialties Research
Phase 3 Completed
NCT01295151 2016-11-02
SWITCH
University of Leeds
Phase 4 Completed
NCT01350804 2016-05-23
NURTURE 1
Novartis
Phase 3 Completed
NCT00048581 2011-11-21
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
Bristol-Myers Squibb
Phase 3 Completed